Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Zai Lab and Cullinan Oncology Announce Strategic Collaboration and License Agreement for .
Zai Lab LimitedDecember 28, 2020 GMT
- Zai Lab to lead development and commercialization of CLN-081 in Greater China
- Cullinan will receive $20 million upfront, up to $211 million in future milestones, and royalties
- Zai Lab to join ongoing global trial for CLN-081
SHANGHAI and SAN FRANCISCO and CAMBRIDGE, Mass., Dec. 28, 2020 (GLOBE NEWSWIRE) Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial-stage biopharmaceutical company, and Cullinan Oncology, a biopharmaceutical company focused on developing a diversified pipeline of targeted oncology and immuno-oncology therapies with transformative potential for cancer patients, today announced an exclusive license agreement for the development, manufacturing and commercialization of CLN-081 in Greater China.
Zai Lab and Cullinan Oncology Announce Strategic Collaboration and License Agreement for CLN-081 in Greater China
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.
VFMCRP and ChemoCentryx Provide Topline Results From ACCOLADE Trial of Avacopan in C3 Glomerulopathy Including Improved Estimated Glomerular Filtration Rate (eGFR)
oaoa.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from oaoa.com Daily Mail and Mail on Sunday newspapers.